CoChat
Sign Up
Cited by 132Diabetes Treatment and ManagementHeart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

Open access
Pratley, Richard E., Tuttle, Katherine R., Rossing, Peter, Rasmussen, Søren, Perkovic, Vlado, Nielsen, Olav Wendelboe, Mann, Johannes F.E., MacIsaac, Richard J., Kosiborod, Mikhail N., Kamenov, Zdravko, Idorn, Thomas, Hansen, Marco Bo, Hadjadj, Samy, Bakris, George, Baeres, Florian M.M., Mahaffey, Kenneth W.·2024·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2024.08.004
Open this paper in CoChat — free account

Abstract

Background People with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at high risk for heart failure (HF) and premature death from cardiovascular (CV) causes. The FLOW (Research Study To See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease), which enrolled participants with T2D and CKD, demonstrated that semaglutide, a glucagon-like peptide-1 receptor agonist, reduced the incidence of the primary composite outcome (persistent ≥50% decline in estimated glomerular filtration rate, persistent estimated glomerular filtration rate 2 , kidney replacement therapy, and kidney or CV death) by 24%. Objectives This prespecified analysis examined the effects of semaglutide on HF outcomes in this high-risk population. Methods Participants were randomized (1:1) to once-weekly subcutaneous semaglutide 1 mg or placebo. The prespecified main outcome was a composite of HF events (new onset or worsening of HF leading to an unscheduled hospital admission or an urgent visit, with initiation of or intensified diuretic/vasoactive therapy) or CV death. HF data were collected by the investigator. CV death was adjudicated by an independent committee. Results A total of 3,533 randomized participants were followed for a median of 3.4 years. HF was present at baseline in 342 participants (19.4%) in the semaglutide group and 336 (19.0%) in the placebo group. In the overall trial population, semaglutide increased time to first HF events or CV d…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2024.08.004

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 28 references

Cited by

Sorted by citations

Items 101–132 of 132

Related

See all

Metadata

Authors
Pratley, R. E., Tuttle, K. R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O. W., Mann, J. F. E., MacIsaac, R. J., Kosiborod, M. N., Kamenov, Z., Idorn, T., Hansen, M. B., Hadjadj, S., Bakris, G., Baeres, F. M. M., & Mahaffey, K. W.
Affiliations
  • AdventHealth Orlando (US)
  • University of Washington (US)
  • University of Copenhagen (DK)
  • Novo Nordisk (Denmark) (DK)
  • UNSW Sydney (AU)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • The University of Melbourne (AU)
  • Saint Luke's Hospital (US)
  • Alexandrovska Hospital (BG)
  • Centre National de la Recherche Scientifique (FR)
  • American Heart Association (US)
  • Stanford Medicine (US)
Corresponding author
Pratley, Richard E.
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2024-10
Volume
84
Issue
17
Pages
1615-1628
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2024.08.004
OpenAlex
W4402066342
Cited by
132
References
28
Citations by year
2026: 55 · 2025: 67 · 2024: 10
FWCI
43.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
  • HAL (submittedVersion, cc-by-nc-nd)
Funders
  • European Commission
  • Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
semaglutide, heart failure, type 2 diabetes, chronic kidney disease, cardiovascular mortality, GLP-1 receptor agonists, FLOW trial, NYHA functional class, heart failure with reduced ejection fraction, renal replacement therapy, heart failure hospitalization, diuretic therapy, cardiovascular risk reduction, SGLT2 inhibitors
MeSH terms
Semaglutide, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review